![Mitchel Berger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mitchel Berger
Directeur/Bestuurslid bij
POLARYX THERAPEUTICS, INC.
Profiel
Mitchel Berger is currently the Director at the American Association of Neurological Surgeons.
Dr. Berger is also an Independent Director at Polaryx Therapeutics, Inc., starting in 2026.
Dr. Berger completed undergraduate education at Harvard College and graduate education at The University of Miami Leonard M.
Miller School of Medicine.
Actieve functies van Mitchel Berger
| Bedrijven | Functie | Begin |
|---|---|---|
| POLARYX THERAPEUTICS, INC. | Directeur/Bestuurslid | 29-01-2026 |
American Association of Neurological Surgeons
 American Association of Neurological Surgeons Miscellaneous Commercial ServicesCommercial Services Operates association of neurological surgeons | Directeur/Bestuurslid | - |
Opleiding van Mitchel Berger
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
24
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
American Association of Neurological Surgeons
American Association of Neurological Surgeons Miscellaneous Commercial ServicesCommercial Services Operates association of neurological surgeons | Commercial Services |
Harvard College
 Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Miami Leonard M. Miller School of Medicine
 The University of Miami Leonard M. Miller School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Polaryx Therapeutics, Inc.
 Polaryx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that engages in discovery, development and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders | Commercial Services |
